Metabolic syndrome in peritoneal dialysis patients

Philip Kam-Tao Li¹, Bonnie Ching-Ha Kwan¹, Cheuk Chun Szeto¹ and Gary Tin-Choi Ko²

¹Department of Medicine & Therapeutics, Prince of Wales Hospital and ²Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China

Abstract

Cardiovascular morbidity and mortality are common in peritoneal dialysis patients. Metabolic syndrome (MES) is a medical condition with a clustering of major risk factors for cardiovascular diseases. In this review article, the various diagnostic criteria used in MES are discussed. It is proposed to use a modified National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) criteria for the diagnosis of MES in peritoneal dialysis (PD) patients taking into consideration the scientific evidence and practicality. When three or more of the following criteria are satisfied in PD patients, obesity, high triglyceride, low high-density lipoprotein cholesterol (HDL-C), hypertension or dysglycaemia, they are diagnosed as having MES. Body mass index (BMI) with reference to ethnicity is suggested to replace waist circumference for diagnosing obesity. Epidemiology and outcome of PD patients with MES are highlighted. The adverse sequela of obesity appear to be primarily due to fat mass rather than non-fat mass, possibly related to the pro-inflammatory effect of adipose tissue. Whilst there are therapies to tackle MES in PD patients, more conclusive data in human studies to see clinically improved outcomes with such strategies are needed.

Keywords: metabolic syndrome; obesity; peritoneal dialysis

Introduction

Metabolic syndrome (MES) is a medical condition with a clustering of major risk factors for cardiovascular diseases and type 2 diabetes [1]. It was also previously termed syndrome X [2], or syndrome of insulin resistance [3]. There are several definitions of MES worldwide. In 1998, Alberti and Zimmet proposed, for the first time, a definition for MES for World Health Organization (WHO) [4]. It consists of insulin resistance and/or dysglycaemia, plus two or more of the following conditions: (i) hypertension = known hypertensive or blood pressure (BP) ≥160/90 mmHg (modified to ≥140/90 mmHg in 1999 [3]); (ii) dyslipidaemia = triglyceride (TG) ≥1.7 mmol/L and/or high-density lipoprotein cholesterol (HDL-C) <0.9 mmol/L in men or <1.0 mmol/L in women; (iii) obesity = waist–hip ratio (WHR) >0.9 in men or >0.85 in women and/or body mass index (BMI) >30 kg/m² and (iv) microalbuminuria = urinary albumin excretion rate ≥20 µg/min or albumin:creatinine ratio ≥20 mg/g.

Dysglycaemia includes known diabetes or impaired glucose tolerance (IGT) or fasting plasma glucose (PG) ≥6.1 mmol/L. There is still no international consensus on a ‘normal range’ for insulin resistance. With euglycaemic clamp technique, insulin resistance is defined in this WHO 1998 criterion as glucose uptake below lowest quartile for background population under investigation [4].

In 1999, the European Group for the Study of Insulin Resistance (EGIR) also proposed a similar definition [6], which requires the measurement of insulin resistance. This EGIR criterion was most impressive by introducing the waist circumference to define obesity, instead of using BMI and WHR. In 2001, the National Cholesterol Education Program (NCEP) Expert Panel (Adult Treatment Panel III) proposed a more simple diagnostic criterion for clinical identification of MES in their third report [7]. According to the NCEP criterion, having three or more of the following conditions are considered diagnostic for MES: obesity (waist circumference >102 cm in men or >88 cm in women), high BP (BP ≥130/85 mmHg or on treatment), dysglycaemia (known diabetes or fasting PG ≥6.1 mmol/L, modified to ≥5.6 mmol/L in 2005 [8]), elevated fasting plasma TG (≥1.7 mmol/L), low HDL-C concentration (<1.0 mmol/L in men or <1.3 mmol/L in women). Due to its simplicity and clinical relevance, the NCEP definition for MES is nowadays the one being most widely used in general populations.

Other definitions of MES include American Association of Clinical Endocrinologists (AACE) criteria proposed in 2003 [9] and International Diabetes Federation (IDF) criteria in 2005 [1]. In particular, the most recently proposed IDF criterion modified the NCEP criterion and highlighted the essential element of central obesity and the need to
Table 1. Comparison of the various definitions of metabolic syndrome in general populations

|                  | WHO, 1998 [4] | EGIR, 1999 [6] | NCEP ATP III, 2001 [7] | IDF, 2005 [1] |
|------------------|---------------|----------------|------------------------|--------------|
| **Insulin resistance** | Known dysglycaemia (diabetes/IFG/IGT) and/or insulin resistance | Insulin resistance | –                      | –            |
| **Obesity**      | BMI > 30 kg/m² or waist-to-hip ratio for men: > 0.9; for women: > 0.85 | ≥ 2 of the following: | ≥ 3 of the following: | ≥ 2 of the following: |
|                  | Plus ≥ 2 of the following: | waist circumference for men: ≥ 94 cm; for women: ≥ 80 cm | Waist circumference for men: ≥ 94 cm; for women: ≥ 80 cm | Waist circumference for men: Plus ≥ 2 of the following: |
|                  | TG: ≥ 1.7 mmol/L; or HDL-C for men: < 0.9 mmol/L; for women: < 1.0 mmol/L | TG: ≥ 1.7 mmol/L | TG: < 1.7 mmol/L | TG: < 1.7 mmol/L |
| **Dyslipidaemia** | Fasting PG ≥ 6.1 mmol/L | Fasting PG ≥ 6.1 mmol/L | Fasting PG ≥ 6.1 mmol/L | – |

WHO, World Health Organization; EGIR, European Group for the study of Insulin Resistance; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; AACE, American Association of Clinical Endocrinology; IDF, International Diabetes Federation; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; BMI, body mass index; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure; PG, plasma glucose; OGTT, oral glucose tolerance test.

aBP cutoff value of the WHO 1998 criteria was revised to 140/90 mmHg in 1999 [5].
bFasting PG cutoff level of the NCEP ATP III 2001 criteria was modified to 5.6 mmol/L in 2005 [8].

consider ethnicity in its definition. Table 1 summarizes these definitions and variations in the thresholds for each category in the different criteria.

**Pathophysiology of metabolic syndrome**

The key element of the constellation of features in MES is obesity as highlighted by the revised criteria for MES by IDF [1,10]. Obesity, especially central obesity, is associated with increased visceral adipose tissue that, being metabolically very active, releases a substantial amount of free fatty acids (FFA) and hence associated with a high serum FFA level.

Adipose tissue can be considered as the largest secretory organ in the body [11,12]. Adipocytes produce a wide range of signalling protein and factors termed adipocytokines [13]. Some of the major adipocytokines include tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), plasminogen activator inhibitor (PAI-1), leptin, monocyte chemotactic protein-1, macrophage migration inhibitory factor and adiponectin. These serve as the signals for the effects of adipocytes on insulin resistance, inflammation, dyslipidaemia, hypertension, endothelial dysfunction and atherosclerosis [14–24]. Excessive fatty acids are also associated with insulin resistance, proinflammatory state and pro-thrombotic state [25,26]. Long-standing hypertension and abnormal blood glucose levels can lead to damage of the kidneys, resulting in albuminuria and even renal failure (see Figure 1).

**Factors to be considered on the diagnostic criteria**

**Obesity—ethnic issues**

Conventionally, obesity is defined as body fat > 25% in males and > 35% in females for young adults [27]. In young Caucasians, these body fat percentages correspond to a BMI of 30 kg/m² while a BMI of 25 kg/m² corresponds to body fat percentages of 20 in males and 30 in females [28]. In accord to these, a BMI cutoff point of ≥ 25–29.9 kg/m² is defined for overweight while ≥ 30 kg/m² for obesity [29].

In the early 1990s, epidemiological studies in Asians have shown that the threshold value of anthropometric
indexes for association with cardiovascular risk factors was considerably lower than those conventionally used in Caucasians [30,31]. This has led to the proposed Asian definition of obesity: BMI ≥ 25 kg/m²; waist circumference ≥ 80 cm in women and ≥90 cm in men [32]. This was followed by a prolific number of reports, albeit many were cohort-based and cross-sectional in nature, on different definitions of obesity in different populations [33,34]. Nevertheless, there is now strong evidence showing that Asian people have more body fat than their Caucasian counterparts for the same BMI [35,36] suggesting the ‘international’ cutoff for general obesity at BMI ≥ 30 kg/m² is too high for Asians. Similar arguments are also applicable to central obesity with the waist circumference cutoff levels among Caucasians at 102 cm (men) and 88 cm (women) are too high and should be modified to 90 cm and 80 cm (men and women respectively) among Asians [37]. The IDF criteria for MES have taken these evidences into consideration and emphasized the ethnic issue in its cutoff levels for obesity [1].

Waist circumference versus BMI

In the first MES criterion by WHO, BMI and WHR were used to define obesity. Nowadays, waist circumference is considered to be a more important surrogate marker than BMI or WHR for the harmful effects of obesity. This has been supported by the findings that visceral fat measurement on CT scan or magnetic resonance imaging correlate better with waist circumference than WHR [38–40]. However, among renal patients undergoing peritoneal dialysis, waist circumference may not reliably reflect abdominal visceral fat content. This is due to the presence of Tenckhoff catheter in situ, lax skin condition after repeated distention of the abdomen by peritoneal dialysis fluid and potential residual peritoneal dialysate inside the abdomen cavity. With all these considerations, BMI may remain the best anthropometric parameter to measure obesity in renal patients undergoing peritoneal dialysis. It has to be emphasized that BMI remains a good measure in defining obesity. One main reason is the widely reported validity of using BMI in categorizing body composition and body fat content [41,42]. There is no doubt that central adiposity does more harm than general adiposity. However, with the above major confounders in measuring the waist properly in patients on peritoneal dialysis, BMI should be the better alternative.

Plasma glucose levels in PD patients

Genuine fasting state could not be achieved in most peritoneal dialysis (PD) patients because of the continuous glucose absorption from dialysate. There is little doubt that PD patients with fasting glucose over 200 mg/dL (11.1 mmol/L) are definitely diabetic, but those with fasting glucose between 126 and 200 mg/dL (7.0 to 11.1 mmol/L) may be considered as having IGT and are not truly diabetic [43]. In addition to the harmful metabolic effect of glucose load on diabetic patients treated by conventional glucose-based peritoneal dialysis solution, newer evidence has accrued that the adverse effect of glucose load applies to peritoneal dialysis patients without pre-existing diabetes mellitus. We studied 252 non-diabetic Chinese patients newly started on continuous ambulatory peritoneal dialysis for the fasting plasma glucose level 1 month after peritoneal dialysis [44]. Fasting plasma glucose was measured by means of a conventional method after an overnight fast, but with continuation of PD therapy with 1.5% dextrose dialysate. We found that the fasting plasma glucose level correlated significantly with the baseline serum C-reactive protein level. Most importantly, our results showed that even mild hyperglycaemia after peritoneal dialysis, with the fasting plasma glucose level > 5.6 mmol/L (100 mg/dL), is associated with worse survival. By multivariate analysis with the Cox proportional hazard model, every 0.6 mmol/L (10 mg/dL) increase in the fasting plasma glucose level conferred 1.6% excess hazard of all-cause mortality [44]. Although a high fasting plasma glucose level 1 month after starting peritoneal dialysis is probably a surrogate indicator of elderly subjects with multiple comorbid conditions and systemic inflammation, fasting plasma glucose level remained an independent predictor of survival after adjusting for age, C-reactive protein level and Charlson’s comorbidity score in our study, suggesting a direct detrimental effect of high glucose level [44].

Table 2. Proposed diagnostic criteria for metabolic syndrome in peritoneal dialysis (PD) patients

| Modified from NCEP ATP III, 2001 criteria |
|----------------------------------------|
| Obesity | ≥ 3 of the following: |
| 1. BMI ≥ 30 kg/m² for Caucasians |
| 2. BMI ≥ 25 kg/m² for Asians |
| 3. BP ≥ 130/85 mmHg or hypertension on treatment |
| Hypertension | 4. BP ≥ 130/85 mmHg or hypertension on treatment |
| Dysglycaemia | 5. Fasting PG ≥ 5.6 mmol/L or diabetic on treatment |

*Body weight for BMI in PD patients is measured either with a dry abdomen or with PD dialysate in abdomen minus X kg (X is the volume in litres of PD dialysate infused).

*Fasting plasma glucose (PG) in PD patients is measured by means of a conventional method after an overnight fast, but with continuation of PD therapy with 1.5% dextrose dialysate. NCEP ATP III, National Cholesterol Education Programme Adult Treatment Panel III; BMI, body mass index; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure.

Proposed diagnostic criteria for metabolic syndrome in PD patients

With all these considerations for diagnosis of metabolic syndrome in PD patients, we propose the following criteria. Modified from NCEP ATP III, 2001 criteria, whenever there are three or more of the following five factors: obesity, high triglyceride, low HDL-C, hypertension or dysglycaemia in PD patients, they are considered having metabolic syndrome (Table 2). These are based on both scientific evidence and practical use of the criteria for making the diagnosis. NCEP criteria, instead of IDF, are chosen since there is accumulating evidence that suggests that the former is much better associated with clinical outcomes.
such as incident coronary heart disease [45,46]. In addition, subjects identified by NCEP criteria are metabolically less favourable and have more insulin resistance than those identified by IDF criteria [47]. Compared to subjects identified by the NCEP definition, subjects identified in excess by IDF showed lower IMT and plaque extent indistinguishable from MES-free subjects [47].

Following the above discussions, we propose to use BMI instead of waist circumference for our PD patients to define obesity. Body weight for BMI in PD patients is measured either with a dry abdomen or with PD dialysate in the abdomen minus $X \times 2$ (where $X$ is the volume in litres of PD dialysate infused). The body weight should be measured when the patient is not fluid overloaded or dehydrated. Fasting plasma glucose (PG) in PD patients is measured by means of a conventional method after an overnight fast, but with continuation of PD therapy with 1.5% dextrose dialysate. This is practically more convenient for our patients coming back for follow-up without the need to drain dry the abdomen the night before. The fasting PG cutoff level of the NCEP ATPIII 2001 criterion was already modified to 5.6 mmol/L in 2005 [8]. In addition, our previous study showed that the fasting plasma glucose level (based on oral fast but without ‘peritoneal fast’) >5.6 mmol/L (100 mg/dL) was already associated with worse survival [44]. Therefore, we used the fasting plasma glucose level (oral fast without ‘peritoneal fast’) >5.6 mmol/L (100 mg/dL) as the criteria for dysglycaemia.

Epidemiology in the general population, CKD and PD patients

Using the NCEP criterion, the Third National Health and Nutrition Examination Survey (NHANES III, 1988–1994) [48] reported the age-adjusted prevalence of MES among the US adult general population as 23.7%, affecting 47 million people. Using the same criterion, ~15–25% of the world’s general population has features of MES [25]. In a population-based study conducted in Hong Kong using the same criterion, 16.7% (age- and gender-adjusted) of the 2893 subjects had MES [49]. The prevalence of MES is much higher in an at-risk group as compared to the general population. The corresponding figures in patients with type 2 diabetes in Northern Europe and Hong Kong were reported to be 80% and 60%, respectively [50,51].

It has previously been reported that those with MES have increased risk of developing chronic kidney disease (CKD). Weir et al. [52] showed that those with three or more criteria of MES had an adjusted odds ratio (OR) of 2.21 of developing CKD. In accord to this, Tanaka’s study in Japan involving >2000 subjects also showed that each of the risk factors in MES (abdominal obesity, high TG, low HDL-C, high fasting PG and hypertension) was associated with the increased prevalence of chronic kidney disease [53]. At the same time, Tanaka et al. [53] found that the prevalence of chronic kidney disease increased with the number of MES risk factors such that the prevalence of chronic kidney disease was 11.0% in those with no metabolic risk factors, 12.5% with one, 15.4% with two, 20.7% with three, and 24.2% with four and 20.0% with five, respectively. Using the absence of MES risk factors as reference, the adjusted OR (95% CI) of developing chronic kidney disease when the number of MES risk factors increased from 1 to 5 were 1.029 (P-value: NS), 1.062 (P-value: NS), 1.206 (P-value: NS), 1.744 (P = 0.0002) and 2.109 (P = 0.0077), respectively [53]. Tanaka’s study used the modified NCEP criteria for MES.

A similar study in a Chinese population showed that the prevalence of chronic kidney disease (estimated-GFR <60 mL/min) and elevated serum creatinine ≥100.8 μmol/L (1.14 mg/dL) in men and ≥85.7 μmol/L (0.97 mg/dL) in women increases with the number of components of metabolic syndrome [54]. In those without any of the components of MES, there was a prevalence of 1.4% chronic kidney disease and this increased to 6.7% if the patients had five components of MES. Likewise, the prevalence of elevated serum creatinine was 4.6% in patients with no components of MES and this increased to 9.5% in those with five components of MES as defined by the NCEP criteria [54].

In a study done by Johnson’s group, the prevalence of MES was 30.5% in a group of 200 subjects with chronic kidney disease stages 4 and 5 [55]. This group included 49 peritoneal dialysis, 78 haemodialysis and 73 pre-dialysis subjects. MES was independently predicted by older age, peritoneal dialysis and Maori/Pacific Islander origin. In this study, the prevalence of MES was highest among those on peritoneal dialysis (50%) [55]. Another recent retrospective, cross-sectional study of 202 incident dialysis patients (94% haemodialysis and 6% peritoneal dialysis) examined the prevalence of the metabolic syndrome at the time of renal replacement therapy initiation [56]. Females represented 39.1% and blacks composed 34.7% of the study population, respectively. Diabetes was the aetiology of ESRD in 44.6% of the patients. Using NCEP criteria, the overall prevalence of the metabolic syndrome was 69.3% in that population and was especially prevalent among diabetic, female and white ESRD patients. Using the proposed modified NCEP criteria in Table 2, our cohort of 212 CAPD patients showed a prevalence of 53.3% (113/212) having MES (PWH unpublished data).

Outcome

MES is associated with a raised level of pro-inflammatory cytokines such as IL-6, TNF-α and a reduced level of nitric oxide and adiponectin. This leads to increased inflammation, vasoconstriction and thrombosis, and hence, an accelerated process of atherosclerosis formation [15,17,18,22,24,57].

The dialysis population has a much higher risk of cardiovascular mortality compared with the general population [58,59]. It has also been shown that among subjects with chronic kidney disease stages 4 and 5, those with MES have a significantly higher risk of mortality (P < 0.05) compared to those without risk factors of MES over a 24-month follow-up [55]. At the same time, in United States, subjects with end-stage renal failure tend to have a higher BMI compared with the general population [60].
A raised BMI in the general population is associated with higher risk of mortality [61–66]. However, it is still not clear whether obesity leads to a better or worse survival outcome in patients on dialysis. Quite a number of studies have shown that in both haemodialysis and peritoneal dialysis patients, higher BMI is associated with improved survival [67–70]. At the same time, some studies showed that survival advantage associated with obesity among chronic dialysis patients is significantly less for peritoneal dialysis patients as compared to haemodialysis patients [71,72]. On the other hand, some studies have shown that a higher degree of obesity leads to worse survival in peritoneal dialysis patients [73]. This negative impact of obesity is associated with a higher hazard ratio of developing peritonitis [74], peritoneal dialysis technique failure [73] and more rapid loss of residual renal function [75].

One reason for the varying association between BMI and survival could be the effect of body composition [76]. In a study on peritoneal dialysis patients, those with a high BMI due to increased fat mass have a worse survival compared to those with a high BMI due to non-fat mass [76]. In other words, incident PD patients with high BMI and normal or high muscle mass have the best survival, and Ramkumar N et al. [76] suggested that PD patients should be encouraged to gain muscle mass rather than fat mass. Our previous study also showed that every 1% increase in lean body mass is associated with a 10% reduction in mortality in our PD patients [69]. In peritoneal dialysis patients, it has been shown that BMI is correlated with IL-6 (r = 0.36, P = 0.018), leptin (r = 0.68, P < 0.001) and C-reactive protein (CRP) (r = 0.31, P = 0.044) [77]. Thus, obesity in patients on peritoneal dialysis may be considered as a pro-inflammatory state [77].

Patients on peritoneal dialysis, compared with those on haemodialysis, might be more at risk of glucose dysregulation, and thus MES. Peritoneal dialysis solutions contain a sizable amount of glucose. Sixty to eighty percent of the glucose instilled into the peritoneal cavity is absorbed, corresponding to 100–300 g of glucose per day [78]. Our group has shown that increased subcutaneous insulin is required in diabetic patients recently commenced on peritoneal dialysis [79]. We also noted a high rate of developing new onset hyperglycaemia among non-diabetic subjects started on peritoneal dialysis [44]. Four weeks after initiation of peritoneal dialysis in 252 non-diabetic Chinese patients, we found that 59 (23.4%) of them developed new onset hyperglycaemia (fasting PG ≥ 7.0 mmol/L or 125 mg/dL) [48 patients (19.0%) had fasting PG between 7.0 and 11.1 mmol/L (126–200 mg/dL) and 11 patients (4.4%) had fasting PG > 11.1 mmol/L (200 mg/dL)] [44]. De novo diabetes mellitus in non-diabetic patients on peritoneal dialysis has also been noted in previous studies and can be in the range of 5% [80,81].

**Interventions**

We should be alert to the possibility of developing MES among our patients started on dialysis. Interventions for MES mainly consist of lifestyle modification. Specific treatment for each of the components is also indicated in selected patients to optimize the effects.

**Abnormal glucose**

Glycaemic control in PD patients consists of lifestyle changes, hypoglycaemic agents and non-glucose-based dialysis solutions. Lifestyle changes take effect through diet, exercise and body weight control. The US Diabetes Prevention Program has demonstrated that the incidence of the metabolic syndrome in a volunteer non-uraemic population was reduced in the lifestyle group compared with placebo [82]. Three-year cumulative incidences of MES were 51% and 34% in the placebo and lifestyle groups, respectively [82].

Thiazolidinediones may also aid the diabetic control. Apart from reducing insulin resistance, thiazolidinediones (peroxisome proliferator-activated receptor-γ agonists) also have a specific anti-inflammatory effect that may be beneficial in patients with renal failure [83]. We previously performed a randomized study in which 52 patients with type 2 diabetes on peritoneal dialysis therapy administered a constant dosage of subcutaneous insulin with stable glycaemic control were randomly assigned to the use of either a fixed dose of rosiglitazone (RSG) plus insulin or insulin alone [84]. After 24 weeks, the percentage reduction in insulin dosage was significantly greater in the RSG group than the control group (−21% versus −0.5%, P = 0.02). Moreover, there appeared to be an anti-inflammatory effect with RSG. At baseline, the two groups had statistically similar CRP levels (RSG versus insulin: 9.35 versus 8.63 mg/L, P = 0.836) while at the end of 24 weeks, the RSG groups had significantly lower CRP levels than the control group (2.21 versus 8.59 mg/L, P = 0.03). Recent studies have shown that more biocompatible and non-glucose-containing dialysis fluids, e.g. icodextrin and amino acid solutions, seem to be associated with improvements in glycaemic control in the diabetic patients on peritoneal dialysis [85].

**Hypertension**

Most subjects with chronic kidney disease and especially those on dialysis tend to have hypertension that usually requires treatment with anti-hypertensive agents. Their BP is partly related to their fluid status, and adequate fluid removal during dialysis can aid in reduction of hypertension. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (The JNC-7 Report) defined BP in the range 120–139/80–89 mmHg as ‘Prehypertension’ [86]. This suggestion is in accord to the concept of ‘prediabetes’ with fasting PG in the range 5.6–6.9 mmol/L as impaired fasting glucose while frank diabetes is defined as the fasting PG level ≥ 7.0 mmol/L. The JNC-7 report also recommends initiating drug therapy for subjects with ‘Prehypertension’ with compelling indications such as chronic kidney disease, heart failure and diabetes. For patients with chronic kidney disease or diabetes, BP < 130/80 mmHg is targeted as treatment goal [86]. Of note is our recent study using an ACE inhibitor in patients on PD [87]. There was benefit of
ACE inhibitor in the preservation of residual renal function in addition to the BP control in PD patients [87].

Obesity

One of the important factors for the constellation of features in MES is obesity. In the general population, reducing obesity, especially reducing visceral obesity, will improve the lipid profile, improve insulin sensitivity and thus better insulin and glucose profile. These will subsequently reduce the susceptibility to thrombosis, decrease the levels of inflammatory markers and improve endothelial function. All these serve to alleviate the risk of coronary heart disease [88]. It was previously shown that plausible relations exist between inflammatory biomarkers, such as IL-6 and high-sensitivity C-reactive protein and regional fat distribution in ESRD patients [89]. Also, increased adipose tissue signalling was found in patients with uraemia that might share some characteristics with the metabolic syndrome of obesity [90].

In PD patients, general measures to reduce weight are similar to that in the non-dialysis population. A multidisciplinary approach to weight reduction is more likely to be successful [91]. This includes individualized meal plans according to energy and nutritional requirements and increasing physical activity. Surgical means such as laparoscopic banding should only be considered for extreme obesity. In the general population, a recent meta-analysis suggested that drugs such as orlistat, sibutramine and rimonabant can modestly reduce weight, have differing effects on cardiovascular risk profiles and have specific adverse effects [92]. However, pharmacotherapy for PD patients with oral anti-obesity drugs is currently not an option due to their limited safety profiles among patients on dialysis.

In the peritoneal dialysis population, avoiding or minimizing peritoneal dialysate glucose, e.g. using icodextrin and amino acid solutions, may aid weight control. A trial using icodextrin compared with 2.5% dextrose peritoneal dialysis fluid showed that patients receiving icodextrin had no increase in weight after 52 weeks, in contrast to a weight gain of almost 2 kg in the dextrose group [93]. Adjusted body weight during the 52-week study for the icodextrin arm was also significantly lower when compared to baseline [93].

Recommendations for weight reduction, especially fat mass, in peritoneal dialysis patients with MES have theoretical advantages. Unfortunately, so far, there is little evidence that weight reduction is associated with improved patient outcomes in peritoneal dialysis.

Hyperlipidaemia

Dyslipidaemia can be treated with reduction in the amount of dietary cholesterol or fats, use of lipid-modifying drugs such as statins or fibrates. There are few large studies concentrating on use of these drugs in the peritoneal dialysis population. Wanner et al. conducted the Deutsche Diabetes Dialyse Studie (4D study) [94] which recruited subjects with type 2 diabetes mellitus receiving maintenance haemodialysis. The 1255 subjects were randomly assigned to receive atorvastatin or placebo. At 4 weeks, the median low-density lipoprotein cholesterol (LDL-C) level had a reduction of 42% in the atorvastatin group, from 3.13 mmol/L (121 mg/dL) to 1.86 mmol/L (72 mg/dL), but only 1.3% in the placebo group, from 3.23 mmol/L (125 mg/dL) to 3.10 mmol/L (120 mg/dL). However, after a median follow-up of 4 years, atorvastatin had no statistically significant effect on the composite primary endpoint of cardiovascular death, nonfatal myocardial infarction and stroke in patients with diabetes receiving haemodialysis. So far we do not have large-scale lipid-lowering trials on survival in PD patients.

The LANDMARK (Longitudinal Assessment of Numerous Discrete Modifications of Atherosclerotic Risk factors in Kidney disease) study [95] assessed a mixed group of haemodialysis, peritoneal dialysis and pre-dialysis patients. Despite having significant improvement in serum LDL-C (−30.9 mg/dL versus −12.7 mg/dL, *P* = 0.001), homocysteine (−6.95 versus −0.67 micromol/L, *P* < 0.001), systolic BP (−6.9 versus −0.2 mmHg, *P* = 0.049) and diastolic BP (−4.8 versus −1.0 mmHg, *P* = 0.043), there was no significant change noted in the carotid intima-media thickness or brachial artery reactivity, as outcome measures of atheroma burden and endothelial function [95]. It was concluded that multiple risk factor intervention programme was not associated with improvement in vascular structure or function in stage 4 or 5 patients with chronic kidney disease. Another study in chronic kidney disease subjects with MES randomized to intensive risk factor modification also did not show any significant difference compared to those on usual care (log-rank score 0.37, *P* = 0.54) [55].

Conclusions

In the general population, MES is associated with increased cardiovascular morbidity and mortality. The prevalence of MES is increasing worldwide, affecting ~15–25% of the general population in most parts of the world. In peritoneal dialysis patients, the prevalence is in the range of ~50%. Previous studies have shown that the presence of MES in those with end-stage renal failure predicts poor survival. Despite some reports that in dialysis patients, a high BMI is associated with a better survival, those with low muscle mass (and thus high fat mass) probably still have a worse survival compared to those with a high muscle mass.

There is evidence that increased cardiovascular risk in the peritoneal dialysis population is due to the interplay between traditional cardiovascular risk factors (metabolic factors) and inflammation. In the general population, improving the metabolic profile can significantly improve the cardiovascular risk. However, evidence in the dialysis population that interventions targeting individual elements of MES can improve outcomes is still pending. Thus, a large-scale interventional research study on the clinical outcome data in this area should be performed.

Acknowledgements. This study was supported in part by the Chinese University of Hong Kong (CUHK) Research Grant Account 6900570 and the Richard Yu CUHK PD Research Fund.

Conflict of interest statement. None declared.
Metabolic syndrome in PD patients

43. Genuith S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–3167

44. Szeto CC, Chow KM, Kwan BC et al. New-onset hyperglycemia in nondiabetic Chinese patients started on peritoneal dialysis. Am J Kidney Dis 2007; 49: 524–532

45. de Simone G, Devereux RB, Chinali M et al. Strong Heart Study Investigators. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the strong heart study. Diabetes Care 2007; 30: 1851–1856

46. Athyros VG, Ganotakis ES, Elisaf MS et al. Comparisons of different definitions of metabolic syndrome. Eur J Clin Invest 2007; 37: 109–116

47. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359

48. Thomas GN, Ho SY, Janus ED et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res Clin Pract 2005; 67: 251–257

49. Isomaa B, Almgren P, Tuomi T et al. Multifactorial definition of the metabolic syndrome. Clinical and epidemiological aspects of vascular disease in chronic renal disease. Diabetes Care 2000; 23: 79–83

50. Isomaa B, Almgren P, Tuominen S et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689

51. Ko GT, So WY, Chan NN et al. Prediction of cardiovascular and total mortality in Chinese type 2 diabetic patients by the WHO definition for the metabolic syndrome. Diabetes Obes Metab 2006; 8: 94–104

52. Weir MR. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am J Hypertens 2005; 18(Pt 2): 100S–105S

53. Tanaka H, Shiohira Y, Uezu Y et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69: 369–374

54. Chen J, Gu D, Chen CS et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant 2007; 22: 1100–1106

55. Johnson DW, Armstrong K, Campbell SB et al. Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification. Nephron (Carlton) 2007; 12: 391–398

56. Young DO, Lund RJ, Haynatzki G et al. Prevalence of the metabolic syndrome in an incident dialysis population. Hemodial Int 2007; 11: 86–95

57. Vudkin JS, Kumari M, Humphries SE et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209–214

58. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(Suppl 3): S112–S119

59. Li PK, Chow KM. The clinical and epidemiological aspects of vascular mortality in chronic peritoneal dialysis patients. Perit Dial Int 2005; 25(Suppl 3): S80–S83

60. Kramer HJ, Saranathan A, Luke A et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453–1459

61. Adams KF, Schatzkin A, Harris TB et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355: 763–778

62. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–1632

63. Hu FB, Willett WC, Li T et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004; 351: 1453–1459

64. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis 1979; 32: 563–576

65. Stevens J, Cai J, Evenson KR et al. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am J Epidemiol 2002; 156: 832–841

66. Stevens J, Plankey MW, Williamson DF et al. The body mass index–mortality relationship in white and African American women. Obes Res 1998; 6: 268–277

67. Johansen KL, Young B, Kaysen GA et al. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80: 324–332

68. Snyder II, Foley RN, Gilbertson DT et al. Body size and outcomes on peritoneal dialysis in the United States. Kidney Int 2003; 64: 1838–1844

69. Szeto CC, Wong TY, Leung CB et al. Dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int 2000; 58: 400–407

70. Wong JS, Port FK, Hulbert-Shearon TE et al. Survival advantage in Asian American end-stage renal disease patients. Kidney Int 1999; 55: 2515–2523

71. Abbott KC, Glantow CW, Trespalacios FC et al. Body mass index, dialysis modality, and survival: analysis of the United States renal data system dialysis morbidity and mortality wave II study. Kidney Int 2004; 65: 597–605

72. Stack AG, Murthy BV, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among ‘large’ ESRD patients in the United States. Kidney Int 2004; 65: 2398–2408

73. McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand dialysis patient populations. J Am Soc Nephrol 2003; 14: 2894–2901

74. McDonald SP, Collins JF, Rumpfheld M et al. Obesity is a risk factor for peritoneitis in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int 2004; 24: 340–346

75. Johnson DW, Mudge DW, Sturtevant JM et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 2003; 23: 276–283

76. Ramkumar N, Pappas LM, Beddu S. Effect of body size and body composition on survival in peritoneal dialysis patients. Perit Dial Int 2005; 25: 461–469

77. Stompor T, Suluowicz W, Dembinska-Kiec A et al. An association between body mass index and markers of inflammation: is obesity the proinflammatory state in patients on peritoneal dialysis? Perit Dial Int 2003; 23: 79–83

78. Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 2000; 20(Suppl 2): S37–S41

79. Szeto CC, Chow KM, Leung CB et al. Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis. Nephrol Dial Transplant 2007; 22: 1697–1702

80. Laneire N, Matthys D, Matthys E et al. Effects of long-term CAPD on carbohydrate and lipid metabolism. Clin Nephrol 1988; 30(Suppl 1): S53–S58

81. Kurtz SB, Wong VH, Anderson CF et al. Continuous ambulatory peritoneal dialysis. Three years’ experience at the Mayo clinic. Mayo Clin Proc 1983; 58: 633–639

82. Orchard TJ, Temprosa M, Goldberg R et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial. Ann Intern Med 2005; 142: 611–619

83. Martens FM, Versser FL, Lemay J et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463–1480

84. Wong TY, Szeto CC, Chow KM et al. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005; 46: 713–719

85. Marshall J, Jennings P, Scott A et al. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003; 64: 1480–1486

86. Chobanian AV, Bakris GL, Black HR et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee.
The seventh report of the joint National committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *JAMA* 2003; 289: 2560–2572

87. Li PK, Chow KM, Wong TY et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. *Ann Intern Med* 2003; 139: 105–112

88. Despres JP, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. *BMJ* 2001; 322: 716–720

89. Axelsson J, Rashid Qureshi A, Suliman ME et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. *Am J Clin Nutr* 2004; 80: 1222–1229

90. Axelsson J, Møller HJ, Witas A et al. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. *Am J Kidney Dis* 2006; 48: 916–925

91. Hollis J, Corden E, Williams PF. Longitudinal evaluation of a weight reduction program for patients on peritoneal dialysis. *Perit Dial Int* 2005; 25(Suppl 3): S152–S154

92. Rucker D, Padwal R, Li SK et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. *BMJ* 2007; 335: 1194–1199

93. Wolfson M, Piraino B, Hamburger RJ et al. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. *Am J Kidney Dis* 2002; 40: 1055–1065

94. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 2005; 353: 238–248

95. Isbel NM, Haluska B, Johnson DW et al. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. *Am Heart J* 2006; 151: 745–753

Received for publication: 6.2.08
Accepted in revised form: 29.5.08